Overview

Azeliragon in MGMT Unmethylated Glioblastoma

Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There's no cure for glioblastoma, which is also known as glioblastoma multiforme. Treatments, including surgery, radiation, and chemotherapy might slow cancer growth and reduce symptoms. New treatments of glioblastoma are needed.
Phase:
Phase 2
Details
Lead Sponsor:
Cantex Pharmaceuticals
Collaborator:
Medpace, Inc.